González-Martínez, Silvia
Kajabova, Viera Horvathova
Pérez-Mies, Belén
Carretero-Barrio, Irene
Caniego-Casas, Tamara
Sarrió, David
Moreno-Bueno, Gema
Gión, María
Perez-García, José
Cortés, Javier
Smolkova, Bozena
Palacios, José http://orcid.org/0000-0002-6730-5066
Funding for this research was provided by:
Universidad de Alcalá
Article History
Received: 2 November 2023
Revised: 8 April 2024
Accepted: 19 April 2024
First Online: 7 May 2024
Declarations
:
: The funders played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript.
: The study received approval from the Local Ethics Committee (Ramón y Cajal Research Ethics Committee reference 223/18) at the Ramón y Cajal University Hospital, 28034 Madrid, Spain.
: Consulting/advisor: Roche, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp&Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmatheuticals, Abbvie. Honoraria: Roche , Novartis , Eisai, Pfizer, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Steamline Therapeutics. Research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Queen Mary University of London, IQVIA. Stock: MAJ3 Capital, Leuko (relative). Travel, accommodation, expenses: Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, Astrazeneca, Gilead, Merck Sharp&Dohme, Steamline. Patents: <i>Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. ISSUED</i>. <i>Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1. LICENSED</i>